Neuromuscular Versus Resistance Training on Functional Capacity in Patients With Heart Failure. (NCT07519473) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
Neuromuscular Versus Resistance Training on Functional Capacity in Patients With Heart Failure.
Pakistan40 participantsStarted 2026-04
Plain-language summary
This randomized controlled trial will compare the effects of neuromuscular training and resistance training on functional capacity, cardiorespiratory fitness, and lower limb performance in patients with chronic heart failure. A total of 40 participants will be randomly assigned into two groups in a single-blinded design.
Both groups will undergo a 10-week supervised exercise program. Outcomes will be assessed using VO₂ peak, 6-Minute Walk Test (6MWT), Short Physical Performance Battery (SPPB), and quality of life measures.
The study aims to determine the more effective rehabilitation approach for improving clinical outcomes in heart failure patients.
Who can participate
Age range
40 Years – 60 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Male and female patients aged 40-60 years
* Diagnosed with chronic heart failure ≥ 1 year
* Heart failure with reduced ejection fraction (HFrEF), EF ≤ 40%
* NYHA Class II-III
* Low to moderate exercise risk (based on Chester Step Test)
* On stable pharmacological treatment for ≥ 6 weeks
* Able to understand and follow exercise instructions
Exclusion Criteria:
* Absolute contraindications to exercise (e.g., recent MI, unstable angina, uncontrolled arrhythmias, severe aortic stenosis, decompensated HF)
* Abnormal CPET findings (severe arrhythmias, ischemia, ST depression)
* Abnormal blood pressure response during exercise
* Exercise-induced angina or thoracic pain
* Musculoskeletal, neurological, or cognitive impairments limiting exercise participation
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Functional Capacity
Timeframe: Baseline and after 10 weeks of intervention
2
Cardiorespiratory Fitness (VO₂ Peak)
Timeframe: Baseline and after 10 weeks of intervention
3
Lower Limb Performance
Timeframe: Baseline and after 10 weeks of intervention